Shuttle Pharmaceuticals Holdings, Inc. SHPH PHARMA
Company Overview
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to treat cancers. It owns a pharmaceutical software artificial intelligence (AI) driven platform for molecular discovery and early-stage drug development. The company was founded in 2012 and is headquartered in Gaithersburg, Maryland.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.06.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- 5-Year Trend Long-term compounding — profit CAGR -44.9%.
Growth & Price Performance
Compounded Profit Growth
| 5 Years: | -44.87% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -90.00% |
| 6 Months: | -64.24% |
| 3 Months: | -26.86% |
| 1 Month: | -18.81% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)47.21 · Neutral
P/E of 35.40 is above the sector median of 24.83 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
CONS
- Earnings shrank at -44.9% CAGR over 5 years.
- Trading 92.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SHPH Shuttle Pharmaceuticals Holdings, Inc. PHARMA | 3.54 | 35.40 | $2.07M | 0.00% | - | - | - | -44.87% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.95M | 3.91M | 2.27M | 2.79M | 2.22M |
| Operating Income | - | - | -242.12K | -638.40K | -353.63K | -821.47K | -1.54M | -1.47M | -1.60M | -1.38M | -1.48M | -3.05M | - | -2.95M | -3.91M | -2.27M | -2.79M | -2.22M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | -3.04M | -3.68M | -2.33M | -2.31M | -1.51M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | 11.93K | 21.74K | 18.90K | 18.25K | 12.12K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -3.05M | -3.71M | -2.35M | -2.61M | -2.15M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -129.32K | -346.80K | -216.96K | -681.84K | -597.27K | -998.42K | -975.10K | -2.18M | -1.79M | -1.73M | -2.03M | -3.78M | - | -3.05M | -3.71M | -2.35M | -2.61M | -2.15M |
| Diluted EPS | - | - | - | - | -0.06 | -0.10 | -0.07 | -1.23 | -0.91 | -0.83 | -24.12 | -39.83 | - | -76.00 | -32.90 | -10.50 | - | -4.30 |
| R&D Expense | - | - | 186.96K | 295.92K | 83.87K | 669.04K | 921.80K | 839.66K | 1.05M | 586.10K | 645.72K | 1.40M | - | 1.57M | 1.03M | 943.48K | - | 267.24K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 2.34M | 5.89M | 7.70M | 11.92M |
| Operating Income | - | -2.34M | -5.89M | -7.70M | -11.92M |
| EBITDA | - | -4.51M | -3.99M | -7.78M | -11.36M |
| Interest Expense | - | 480.70K | 2.60M | 1.36M | 70.83K |
| Pretax Income | - | -5.00M | -6.59M | -9.14M | -11.72M |
| Tax Provision | 0 | 0 | - | - | - |
| Net Income | - | -5.00M | -6.59M | -9.14M | -11.72M |
| Diluted EPS | - | -1,260.00 | -882.50 | -826.00 | -71.60 |
| R&D Expense | 1.02M | 1.15M | 3.52M | 3.62M | 4.05M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | - | - | 8.65M | 5.95M | 2.51M | 10.48M |
| Current Assets | - | - | 8.58M | 5.59M | 2.21M | 502.91K |
| Cash & Equivalents | - | - | 8.42M | 2.58M | 1.92M | 334.00K |
| Inventory | - | - | - | - | - | - |
| Receivables | - | 0 | - | - | - | - |
| Total Liabilities | - | - | 975.68K | 1.90M | 1.80M | 8.22M |
| Current Liabilities | - | - | 975.68K | 1.04M | 1.53M | 7.97M |
| Long Term Debt | - | - | - | 135.09K | - | - |
| Total Debt | - | - | 748.30K | 1.09M | 1.17M | 232.15K |
| Total Equity | -1.69M | - | 7.68M | 4.06M | 709.15K | 2.25M |
| Shares Outstanding | - | - | 6.80K | 8.03K | 16.31K | 202.36K |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -2.67M | -5.58M | -7.33M | -9.48M |
| Investing Cash Flow | - | 0 | -2.83M | 2.92M | -3.06M |
| Financing Cash Flow | - | 10.58M | 2.57M | 3.76M | 10.95M |
| Capital Expenditure | - | - | -19.05K | - | -3.06M |
| Free Cash Flow | - | -2.67M | -5.60M | -7.33M | -12.54M |
| Net Change in Cash | - | 7.91M | -5.84M | -656.27K | -1.59M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | - | -65.1% | -162.6% | -1,289.5% | -519.9% |
| ROCE % | - | -30.5% | -120.0% | -791.4% | -474.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | HRT Financial LP | 7.65% | 78.60K | $252.30K |
| 2 | Citadel Advisors Llc | 2.37% | 24.35K | $78.18K |
| 3 | Barclays Plc | 0.07% | 750 | $2.41K |
| 4 | Tower Research Capital LLC (TRC) | 0.04% | 389 | $1.25K |
| 5 | Kelleher Financial Advisors | 0.01% | 120 | $385 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SHPH
Shuttle Pharmaceuticals Holdings, Inc. Announces Receipt of NASDAQ Noncompliance Letter
Gaithersburg, Maryland--(Newsfile Corp. - August 28, 2026) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) (the "Company" or "Shuttle"), today announced that the Company is not in compliance with the periodic filing requirements for…
Shuttle to Acquire United Dogecoin in Push to Build Public DOGE Mining Platform
Shuttle Pharmaceuticals Holdings (NASDAQ: $SHPH) said it has signed a definitive merger agreement to acquire United...
SHPH, ILLR, IVF: Why These Stocks Posted Double-Digit Gains After-Hours Today
AI infrastructure plan, SpaceX exposure, and Nasdaq compliance update boosted investor sentiment.
RETRANSMISSION: Shuttle Pharmaceuticals Launches Autonomous Self Reasoning AI Agent for Scientific Workflows
Gaithersburg, Maryland--(Newsfile Corp. - March 27, 2026) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) ("Shuttle Pharma" or the "Company"), today announced a major advancement to its molecule.ai platform, significantly expanding …
Shuttle Pharmaceuticals Launches Autonomous Self Reasoning AI Agent for Scientific Workflows
Gaithersburg, Maryland--(Newsfile Corp. - March 26, 2026) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) ("Shuttle Pharma" or the "Company"), today announced a major advancement to its molecule.ai platform, significantly expanding …
E.F. Hutton & Co. Serves as Exclusive Placement Agent on Shuttle Pharmaceuticals’ $3.5 Million Public Offering
NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co. (“E.F. Hutton”), a leading investment banking and financial advisory firm, today announced that it acted as the exclusive placement agent in connection with a $3.5 million publi…
SHPH — Frequently Asked Questions
What is the current share price of Shuttle Pharmaceuticals Holdings, Inc. (SHPH)?
As of 2026-09-19 21:16 PDT, Shuttle Pharmaceuticals Holdings, Inc. (SHPH) trades at $3.54 on NasdaqCM. Its 52-week range is $2.78 to $47.60.
What is the market capitalisation of SHPH?
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) has a market capitalisation of $2.07M on NasdaqCM.
What is the P/E ratio of SHPH?
SHPH trades at a trailing price-to-earnings (P/E) ratio of 35.40. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.53.
Is SHPH a good stock to buy?
This page provides a data-driven analysis of Shuttle Pharmaceuticals Holdings, Inc. (SHPH), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.